Heron Therapeutics (NASDAQ:HRTX)‘s stock had its “buy” rating reiterated by equities researchers at Cowen in a research note issued to investors on Wednesday. They currently have a $40.00 price target on the biotechnology company’s stock. Cowen’s price target indicates a potential upside of 160.25% from the company’s previous close.

HRTX has been the subject of several other research reports. Noble Financial restated a “buy” rating and issued a $24.00 price objective on shares of Heron Therapeutics in a research report on Friday, October 6th. Cantor Fitzgerald restated a “buy” rating on shares of Heron Therapeutics in a research report on Monday, September 25th. Zacks Investment Research upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Oppenheimer initiated coverage on shares of Heron Therapeutics in a research report on Monday, October 30th. They issued a “buy” rating and a $27.00 price objective for the company. Finally, Mizuho restated a “buy” rating and issued a $28.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, November 7th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $28.73.

Heron Therapeutics (NASDAQ HRTX) traded down $0.13 during mid-day trading on Wednesday, reaching $15.37. 918,200 shares of the company traded hands, compared to its average volume of 838,581. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. Heron Therapeutics has a 1 year low of $12.21 and a 1 year high of $18.40.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The firm had revenue of $8.57 million during the quarter, compared to analysts’ expectations of $8.12 million. sell-side analysts forecast that Heron Therapeutics will post -3.42 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Parametric Portfolio Associates LLC grew its holdings in Heron Therapeutics by 2.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock worth $470,000 after acquiring an additional 771 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in shares of Heron Therapeutics by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock valued at $2,363,000 after buying an additional 1,026 shares during the period. Legal & General Group Plc grew its holdings in shares of Heron Therapeutics by 13.9% in the 1st quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 1,098 shares during the period. HighTower Advisors LLC grew its holdings in shares of Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after buying an additional 1,700 shares during the period. Finally, Tudor Investment Corp ET AL grew its holdings in shares of Heron Therapeutics by 10.2% in the 2nd quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock valued at $258,000 after buying an additional 1,724 shares during the period.

ILLEGAL ACTIVITY WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/07/cowen-reiterates-buy-rating-for-heron-therapeutics-hrtx.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.